Contact Us for our BEST PRICE Now! +44 843 557 6440 Email Us Request a Sample
Follow RSS for latest reports on this topicHumira - Market Research and Reports
Technical background:
HUMIRA is a tumor necrosis factor (TNF) blocker - further details can be viewed:
- Tumor Necrosis Factor TNF
- Cytokine Tumour Necrosis Factor (TNF)
Mechanism of Action:
- Adalimumab is a recombinant human anti-TNF monoclonal antibody
- It complexes with soluble TNF-α and prevents its interaction with p55 and p75 surface receptors; this results in a down-regulation of macrophage & T cell function
Indications:
HUMIRA is manufactured by Abbott Laboratories and has been approved as a prescription medicine indicated for the treatment of:
- Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in pediatric patients 4 years of age and older.
- Psoriatic Arthritis: HUMIRA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
- Ankylosing Spondylitis: HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- Crohn's Disease: HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.
- Plaque Psoriasis: HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
Related Reports:
We found 3 reports that matched your search.
Refine your search, and find more matches, using the form above.
Humira- Drug Insight, 2018 [Report Updated: 14-02-2018]
IntroductionDelveInsight's pharmaceuticals report, Humira Drug Insight, 2018 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Humira covering the historical global sales and also provides the Humira sales estimation during the forecasted period (2018-2020). The report also...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$1000
Global and Chinese Humira Industry, 2017 Market Research Report [Report Updated: 19-12-2017]
The 'Global and Chinese Humira Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Humira industry with a focus on the Chinese market. The report provides key statistics on the market status of the Humira manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, ...Read More >>>
Published:
2017-12-19
Published by: Prof Research
Prices Starting From:
$3000
Humira- Drug Insights, 2017 [Report Updated: 10-07-2017]
DelveInsight’s pharmaceuticals report, “ Humira Drug Insights, 2017” highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Humira covering the historical global sales and also provides the Humira sales estimation during the forecasted period (2017-2019). The report also co...Read More >>>
Published:
2017-07-10
Published by: Delve Insight
Prices Starting From:
$1000